Yue Meiting, Qin Zhen, Hu Liang, Ji Hongbin
State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China.
University of Chinese Academy of Sciences, Beijing 100049, China.
Chin Med J Pulm Crit Care Med. 2024 Mar 20;2(2):95-105. doi: 10.1016/j.pccm.2024.02.003. eCollection 2024 Jun.
Cancer cachexia is a multifactorial syndrome characterized by loss of body weight secondary to skeletal muscle atrophy and adipose tissue wasting. It not only has a significant impact on patients' quality of life but also reduces the effectiveness and tolerability of anticancer therapy, leading to poor clinical outcomes. Lung cancer is a prominent global health concern, and the prevalence of cachexia is high among patients with lung cancer. In this review, we integrate findings from studies of lung cancer and other types of cancer to provide an overview of recent advances in cancer cachexia. Our focus includes topics such as the clinical criteria for diagnosis and staging, the function and mechanism of selected mediators, and potential therapeutic strategies for clinical application. A comprehensive summary of current studies will improve our understanding of the mechanisms underlying cachexia and contribute to the identification of high-risk patients, the development of effective treatment strategies, and the design of appropriate therapeutic regimens for patients at different disease stages.
癌症恶病质是一种多因素综合征,其特征是继发于骨骼肌萎缩和脂肪组织消耗的体重减轻。它不仅对患者的生活质量有重大影响,还会降低抗癌治疗的有效性和耐受性,导致临床预后不良。肺癌是全球突出的健康问题,恶病质在肺癌患者中的患病率很高。在本综述中,我们整合了肺癌及其他类型癌症的研究结果,以概述癌症恶病质的最新进展。我们关注的主题包括诊断和分期的临床标准、选定介质的功能和机制以及临床应用的潜在治疗策略。对当前研究的全面总结将增进我们对恶病质潜在机制的理解,并有助于识别高危患者、制定有效的治疗策略以及为不同疾病阶段的患者设计合适的治疗方案。